# Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/adjuvant-sintilimab-in-resected-high-risk-hepatocellular-carcinoma-a-randomized/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Kang Wang,Yan‐Jun Xiang,Hongming Yu,Yuqiang Cheng,Zong‐Han Liu,Yingyi Qin,Jie Shi,Wei‐Xing Guo,Chong‐De Lu,Yaxin Zheng,Feiguo Zhou,Mao-Lin Yan,Hongkun Zhou,Chao Liang,Fan Zhang,Wenjing Wei,Wan Yee Lau,Jing‐Jing Li,Yanfang Liu,Shuqun Cheng |
| Citations | 129 |
| DOI | 10.1038/s41591-023-02786-7 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4391027452 |
| PMID | 38242982 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Jie Shi](https://scholariq.org/researchers/jie-shi/)

## Paper journal

- [Nature Medicine](https://scholariq.org/journals/nature-medicine/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Mechanisms and Therapy](https://scholariq.org/topics/cancer-mechanisms-and-therapy/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.